March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...
Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment. Background: Medical castration using gonadotropin-releasing hormone (GnRH) ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality ...
Chemotherapy for breast cancer in premenopausal women causes menopause (premature ovarian failure) in a variable proportion of patients, ranging from 0% to 90% depending on the treatment received and ...
LIBELULATM trial completed enrollment of Central Precocious Puberty (CPP) patients in North and South America, advancing the path for Debio 4326, a triptorelin injectable 12-month extended-release ...
Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding ...
HealthDay News — For premenopausal women with breast cancer, chemotherapy plus the luteinizing hormone-releasing hormone analogue (LHRHa) triptorelin is associated with higher long-term probability of ...
Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback